Literature DB >> 19253813

Hearing aids for Ménière's syndrome: implications of hearing fluctuation.

Celene McNeill1, Catherine M McMahon, Philip Newall, Mary Kalantzis.   

Abstract

BACKGROUND: Hearing fluctuation imposes the biggest challenge in the fitting of hearing aids for patients with Ménière's syndrome.
PURPOSE: This study shows that the problem maybe be overcome by allowing the patients to test their own hearing and to program their own hearing aids to adjust for hearing fluctuation. RESEARCH DESIGN AND STUDY SAMPLE: A group of 40 participants diagnosed with Ménère's syndrome were fitted with Widex Senso Diva hearing aids and were provided with a portable Senso Programmer 3 (SP3) that allowed them to measure their own hearing thresholds at up to 14 different frequencies and to program their own devices. INTERVENTION: The participants were instructed to test their hearing three times a day for 8 weeks and to program their hearing aids according to the measured thresholds. DATA COLLECTION AND ANALYSIS: All participants recorded some degree of hearing fluctuation during the 8-week trial. RESULTS AND
CONCLUSIONS: Among participants, 70 percent continued to program their hearing aids on a regular basis and reported great satisfaction with amplification because they are now able to adjust their own devices when their hearing fluctuates.

Entities:  

Mesh:

Year:  2008        PMID: 19253813     DOI: 10.3766/jaaa.19.5.5

Source DB:  PubMed          Journal:  J Am Acad Audiol        ISSN: 1050-0545            Impact factor:   1.664


  2 in total

1.  Vestibulo-Cochlear Function After Cochlear Implantation in Patients With Meniere's Disease.

Authors:  Raquel Manrique-Huarte; Diego Calavia; Laura Alvarez-Gomez; Alicia Huarte; Nicolás Perez-Fernández; Manuel Manrique
Journal:  J Int Adv Otol       Date:  2018-04       Impact factor: 1.017

2.  Speech Recognition During Follow-Up of Patients with Ménière's Disease: What Are We Missing?

Authors:  Octavio Garaycochea; Raquel Manrique-Huarte; Diego Calavia; Laura Girón; Nicolás Pérez-Fernández
Journal:  J Int Adv Otol       Date:  2022-01       Impact factor: 1.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.